Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$1.04B+12778.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian R. Kahn CFA
- Sector
- Consumer Cyclical
- Industry
- Specialty Retail
- Employees
- 8,575
- Beta
- 1.69
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.59
Financials
Revenue
$1.04B+12778.9%Net Income
$-50.80MEBITDA
$41.15MFree Cash Flow
$3.86MEPS (diluted)
$-1.44Shares Outstanding (diluted)
35.18M+172.8%Operating Expenses
$383.56MCash & Debt
$106.26MReturn of Capital
$24.11MRevenue by Segment (annual)
$29.58MDividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $4.40B | $-68.57M | $-1.74 |
| 2021 | $3.26B | $191.97M | $4.78 |
| 2020 | $2.03B | $10.94M | $0.32 |
| 2018 | $132.55M | $-2.16M | $-0.16 |
| 2017 | $174.87M | $135.0K | $0.01 |
| 2016 | $173.99M | $13.01M | $0.94 |
| 2015 | $173.43M | $19.42M | $1.41 |
| 2014 | $162.17M | $8.69M | $0.63 |
| 2013 | $159.70M | $21.98M | $1.57 |
| 2012 | $147.61M | $17.63M | $1.26 |
| 2011 | $109.10M | $17.41M | $1.48 |
| 2010 | $85.41M | $15.76M | $1.29 |
| 2009 | $84.63M | $11.00M | $0.97 |
Valuation
FRGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
151+202.50%Social Signal Score
Mentions (38)
- Newsseekingalpha.com·5d ago·Neutral
Disney: One Franchise, Several Ways To Make Money The Walt Disney Company remains a bullish opportunity as its IP flywheel connects content, streaming, merchandise, sports, and experiences. DIS's Experiences business is a cash cow with expansion potential: Q4 revenue rose 15% and operating income 20%, aided by an extra week. DIS's streaming ecosystem offers subscriber, ARPU, margin, and cross-selling upside, though integration and a potential free tier carry execution and dilution risks.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise RemeGen's expertise and next generation engineering expand Vor Bio's leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high potency and extended half-life for potentially best-in-class efficacy and dosing RC298 is in IND-enabling development, with an initial regulatory filing anticipated in the first half of 2
View source ↗ - Newsbusinesswire.com·12d ago·Neutral
FSC Franchise Co. Selects PAR Technology for Loyalty, Ordering, and Catering Partner Across Its Restaurant Brands NEW HARTFORD, N.Y.--(BUSINESS WIRE)--PAR Technology Corporation (NYSE: PAR), a leading technology provider powering multi-unit operators across restaurant, retail, and large-scale commerce, today announced that FSC Franchise Co. ("FSC"), franchisor of Beef ‘O' Brady's, The Brass Tap, and Newk's Eatery, has selected PAR® Punchh®, PAR Ordering™, and PAR Catering as its recommended solu
View source ↗ - Newszacks.com·16d ago·Neutral
Charter Q3 Earnings Beat on Debt Gain Amid Franchise Impairment CHTR beats Q3 earnings estimates as Cox lifts revenues, but a $6.33B franchise impairment, Internet subscriber losses and declining cash flow cloud results.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Tactile Systems Technology: The Paperwork Moat Behind A Mispriced Lymphedema Franchise Tactile Systems Technology is undervalued, trading at a deep discount despite double-digit lymphedema growth and sector-leading 77% gross margins. TCMD's competitive moat widens as Medicare prior authorization requirements increase, favoring scale and established reimbursement infrastructure. LymphaTech acquisition and potential CPT code approval could unlock significant new diagnosis-driven growth, reinforcin
View source ↗ - Newsnewsfilecorp.com·20d ago·Neutral
Happy Belly Food Group's Heal Wellness Signs Binding Agreement for 150 Heal Wellness Franchise Units Across the State of Texas, USA Toronto, Ontario--(Newsfile Corp. - November 2, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce its largest franchise development agreement in company history, with the signing of a binding 150 Heal Wellness restaurants ("Heal") in the State
View source ↗ - Newsbenzinga.com·24d ago·Negative
Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027 Merck & Co. Inc. (NYSE:MRK) stock edged higher Thursday after the drugmaker reported third-quarter results that topped Wall Street revenue expectations and upbeat financial guidance.
View source ↗ - Newsnewsfilecorp.com·27d ago·Neutral
Stardust Expands Across Ontario's Cottage Country with New Franchise Serving Muskoka, Kawartha Lakes, Peterborough and Haliburton Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Stardust Solar Energy Inc. (TSXV: SUN) (OTCQB: SUNXF) (FSE: 6330) ("Stardust" or the "Company"), a leading North American franchisor of renewable energy installation services, is pleased to announce the launch of its newest Canadian franchise serving Muskoka, Kawartha Lakes, Peterborough, and Haliburto
View source ↗ - Newsseekingalpha.com·31d ago·Neutral
Houlihan Lokey Q2 Earnings Preview: A Resilient Franchise With Something To Prove Houlihan Lokey remains a leading diversified financial advisory firm, with a strong franchise and tenured management team. HLI's Corporate Finance segment faces temporary headwinds, but record backlog and stable transaction activity suggest underlying demand remains resilient. Revenue per transaction is declining in Corporate Finance, while Financial Restructuring and Valuation Advisory offer meaningful diversifica
View source ↗ - Newsseekingalpha.com·33d ago·Neutral
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise Madrigal Pharmaceuticals is transitioning from hypergrowth to a self-funding franchise, with Rezdiffra now covering enterprise costs ahead of key 2027 data. Q2 net sales grew 71% to $364.3M, with over 50,000 patients on Rezdiffra and gross margins at 89%, indicating strong underlying fundamentals and low market penetration (~11%). Despite a headline loss, recurring cash operations are breakeven or slightly pos
View source ↗ - Newsnewsfilecorp.com·33d ago·Neutral
Stardust Solar Launches Manitoba Franchise in Partnership with Established Electrical Contractor Vancouver, British Columbia--(Newsfile Corp. - October 20, 2026) - Stardust Solar Energy Inc. (TSXV: SUN) (OTCQB: SUNXF) (FSE: 6330) ("Stardust Solar" or the "Company"), a North American provider of solar energy solutions, is pleased to announce the launch of Stardust Solar Manitoba, its newest Canadian franchise. The province-wide franchise will be led by the experienced management team behind South
View source ↗ - Newsbusinesswire.com·34d ago·Positive
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targete
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Snail Games Subsidiary Interactive Films Launches The Fame Game II: L.A. Heartbreaker, Expanding Its Interactive Hollywood Drama Franchise CULVER CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced the launch of The Fame Game II: L.A.
View source ↗ - Newsglobenewswire.com·38d ago·Positive
Established American Buffet Chain Adopts Beyond Oil as Sole Sourced Frying Standard Across Corporate and Franchise Locations Following a successful pilot, family-oriented buffet chain has selected Beyond Oil for its corporate and franchise locations as a sole source partner, establishing it as a best practice for its operations. Following a successful pilot, family-oriented buffet chain has selected Beyond Oil for its corporate and franchise locations as a sole source partner, establishing it as
View source ↗ - Newsseekingalpha.com·41d ago·Positive
MTY Food Group: A High-Margin Franchise Cannibal Trading At A 17.82% FCF Yield MTY Food Group is rated a strong buy, trading at just 5.61x P/FCF with a 6.31% dividend yield. MTY shifts focus to its high-margin franchised segment, downsizing volatile corporate stores to enhance cash flow reliability. The company announced a 35% dividend hike and plans to restore share buybacks, targeting higher shareholder yield and FCF/share growth.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Beyond Oil Announces Commercial Rollout Across 60 Franchise Locations of Leading Global Fast-Food Brand Following Global Vendor Approval Milestone marks the first regional franchise group to complete pilot evaluation and advance to commercial deployment following the multinational restaurant parent company's global vendor approval
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise
View source ↗ - Newsnewsfilecorp.com·53d ago·Negative
Stardust Strengthens Franchise Network Through Strategic Territory Optimization Vancouver, British Columbia--(Newsfile Corp. - September 30, 2026) - Stardust Solar Energy Inc. (TSXV: SUN) (OTCQB: SUNXF) (FSE: 6330) ("Stardust Solar" or the "Company"), a North American renewable energy company focused on distributed energy, commercial solar, utility-scale development and long-term renewable energy asset ownership, announces a strategic optimization of its franchise network designed to strengthen
View source ↗ - Newsglobenewswire.com·54d ago·Positive
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone
View source ↗ - Newsseekingalpha.com·59d ago·Neutral
Manchester United: Ride The Sports Franchise Valuation Wave Up Manchester United plc trades at a significant discount to recent sports franchise valuations, despite improved financials and revenue growth. MANU's market cap of $3.6 billion is roughly half of Forbes' estimated $7.2 billion valuation, highlighting a substantial disconnect. Recent sports franchise transactions and rising TV rights revenues suggest substantial upside for MANU, with scarcity value supporting higher multiples.
View source ↗ - Newszacks.com·60d ago·Neutral
Goldman Eyes Palmer Square Buyout to Strengthen Credit & AWM Franchise GS is in talks to acquire Palmer Square, potentially boosting its credit capabilities, AWM franchise and recurring fee revenues.
View source ↗ - Newszacks.com·62d ago·Neutral
XYZ's Square Deepens Ideal Nutrition Partnership as Franchise Expands Block's Square expands its Ideal Nutrition partnership as the meal company targets 20 stores by 2026 and explores new markets beyond Florida.
View source ↗ - Newsglobenewswire.com·65d ago·Neutral
BetMGM Begins Building “The Traitors” Franchise with the Launch of The Traitors™ Faithful Riches in Alberta and Ontario Exclusive agreement with All3Media International, part of media and entertainment group, Banijay Entertainment, brings the hit television phenomenon to BetMGM Casino and establishes the foundation for a growing portfolio of iGaming content Exclusive agreement with All3Media International, part of media and entertainment group, Banijay Entertainment, brings the hit television ph
View source ↗ - Newsseekingalpha.com·65d ago·Positive
Vor Biopharma: A Funded Replication Story With Franchise Potential Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success.
View source ↗ - Newsprnewswire.com·66d ago·Negative
Bank7 Corp. to Acquire Century Financial Services Corporation and Expand Southwest Franchise into New Mexico OKLAHOMA CITY, Sept. 17, 2026 /PRNewswire/ -- Bank7 Corp. (NASDAQ: BSVN) (the "Company"), the parent company of Oklahoma City-based Bank7, and Century Financial Services Corporation ("Century"), the Santa Fe, New Mexico-based bank holding company for Century Bank, jointly announce today that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") to which
View source ↗ - Newsseekingalpha.com·75d ago·Negative
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
ZenaTech Plans Franchise Business Model for Drone as a Service Power Washing VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces it is developing a franchise business strategy and plan to bring branded, drone-based power washing servi
View source ↗ - Newsseekingalpha.com·76d ago·Positive
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over
View source ↗ - Newsmarketbeat.com·76d ago·Positive
Why Franchise Models Are Winning the Restaurant Stock Divide Lower-income consumers have been pulling back on spending. But the impact on quick-service restaurant stocks hasn't been the same.
View source ↗ - Newsseekingalpha.com·79d ago·Negative
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 response rates and clean safety, with monthly dosing and efficacy across both biologic-experienced and naive patients. AVTX's $472M cash position secures operations into 2029, reducing near-term dilution risk and enha
View source ↗ - Newsseekingalpha.com·79d ago·Neutral
Redwood Trust: Legacy Losses Obscure A Profitable Mortgage Banking Franchise Redwood Trust is rated Buy with a 12-month base case price target of $5.52, reflecting a 35% total return potential. RWT trades at a 33% discount to GAAP book value, as the market over-penalizes legacy asset risks despite strong core mortgage banking performance. Core platforms delivered a 33% annualized return on capital and robust volume growth, but legacy losses continue to drag on consolidated earnings and dividend
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Esquire Bank Named a Top Deposit Franchise by S&P Global Market Intelligence for Third Consecutive Year JERICHO, N.Y., Sept. 2, 2026 /PRNewswire/ -- Esquire Financial Holdings, Inc. (NASDAQ: ESQ) ("Esquire"), the parent company for Esquire Bank, National Association ("Esquire Bank" or the "Bank") (collectively "Esquire"), today announced the Bank's inclusion in S&P Global Market Intelligence's annual U.S. Community Bank Deposit Rankings for the third consecutive year.
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
First Financial Corporation and First Illinois Corporation Sign Merger Agreement Transaction Strengthens First Financial's Illinois Franchise Through Addition of Hickory Point Bank and Trust Transaction Strengthens First Financial's Illinois Franchise Through Addition of Hickory Point Bank and Trust
View source ↗ - Newsseekingalpha.com·93d ago·Positive
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials, with $436.1M in cash expected to last into 2H 2029, but it will likely need more capital before commercial launch. RAP-219's long half-life offers a 'forgiveness' advantage for missed doses, but regulatory scrutiny
View source ↗ - Newsseekingalpha.com·96d ago·Negative
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while str
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulato
View source ↗
Earnings
Typical surprise -2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 8$-0.22 vs $0.27miss
- Wed, May 10$0.11 vs $0.38miss
- Tue, Feb 28$0.47 vs $0.18beat
- Thu, Nov 3$0.59 vs $0.72miss
- Thu, Aug 4$1.19 vs $1.28miss
- Thu, May 5$1.29 vs $1.08beat
Estimates and results for FRG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FRG officers and directors.
- Bought
- —
- Sold
- —
0 trades
5 trades
- Riley Richard Wsold
- Paulson Randall Esold
- Kelleher Thomas J /advsold
- Ondeck Daniel Meitnersold
- Riley Bryant Rsold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FRG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
